This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moss, R. B.
Right arrow Articles by Carlo, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moss, R. B.
Right arrow Articles by Carlo, D. J.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, September 2000, p. 724-727, Vol. 7, No. 5
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

T-Helper-Cell Proliferative Responses to Whole-Killed Human Immunodeficiency Virus Type 1 (HIV-1) and p24 Antigens of Different Clades in HIV-1-Infected Subjects Vaccinated with HIV-1 Immunogen (Remune)

Ronald B. Moss,1,* Wieslawa Giermakowska,1 Mark R. Wallace,2 Jay Savary,1 Fred Jensen,1 and Dennis J. Carlo1

The Immune Response Corporation, Carlsbad, California 92008,1 and Division of Infectious Diseases, U.S. Naval Hospital, San Diego, California 921342

Received 6 April 2000/Returned for modification 9 May 2000/Accepted 16 May 2000

The discovery of multiple subtypes of human immunodeficiency virus type 1 (HIV-1) worldwide has created new challenges for the development of both therapeutic and preventive AIDS vaccines. We examined T-helper proliferative responses to HIV-1 clade A, B, C, G, and E whole-killed virus and to HIV-1 clade G and B core (p24) antigens in HIV-1-infected subjects taking potent antiviral drugs who received HIV immunogen (Remune) therapeutic vaccination. Subjects who were immunized mounted strong proliferative responses to both whole virus and core antigens of the different clades. These results suggest that a whole-killed immunogen may have broad applications as a therapeutic as well as a preventive vaccine in the current multiclade HIV-1 pandemic.

* Corresponding author. Mailing address: The Immune Response Corporation, 5935 Darwin Court, Carlsbad, CA 92008. Phone: (760) 431-7080. Fax: (760) 431-8636. E-mail: shotdoc{at}imnr.com.

Clinical and Diagnostic Laboratory Immunology, September 2000, p. 724-727, Vol. 7, No. 5
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.




Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»